9:02
Nina Le Bert - T cell cross-reactivity with SARS, other HCoVs and possibly other animal Beta-CoVs
4:24
Kulldorff/Gupta/Bhattacharya - Viral circulation at an endemic equilibrium
5:17
Sunetra Gupta - A very logical other proposition is: let infections rise and protect the vulnerable
3:34
John Ioannidis - Education, schools, extremely low risk on children
4:28
John Lee - Studies show that 40% to 80% of people have T-cell cross-reactivity to this coronavirus
2:34
John Ioannidis - Vaccines: "I'm a little bit on the pessimistic side"
1:12
Anders Tegnell - On Masks - The evidence for the effect is very weak
8:39
Michael Levitt - What we need to really do is: control the panic.
:46
Karol Sikora - Public Health England and Oxford Immunotec T cell study - Pre-existing immunity
4:16
Sunetra Gupta - It is incorrect to state that any rise in cases is DRIVEN by a variant
1:36
Sunetra Gupta - Elderly more connected with grandchildren in the past may have more resistance
:32
Jay Bhattacharya - There are by now 70 to 100 Million estimated infections in the US
1:55
John Ioannidis - The Influenza toll. The Naming of SARS-CoV-2. The Russian Flu of 1889 and HCoV-OC43
3:51
Michael Yeadon - The seroprevalence is now about 10 times lower than the false positive rate
10:02
Hendrik Streeck - We cannot presume something from statistical isolated incidents
4:19
Beda Stadler - Cross-reactivity - The question of how many antibodies are providing immunity
25:23
Antonio Bertoletti - Asymptomatic SARS-CoV-2 mount a very robust antigene-specific T cell response
12:22
Gupta/Kulldorff/Bhattacharya/Atlas - March 18, 2021 - On lockdowns
:53
Jay Bhattacharya - The lockdown strategy extends the epidemic into the indefinite future
1:40
Gabriela Gomes - Herd Immunity will be reach by the end of the year: it becomes seasonal
